Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Neurotrope Inc (NQ: NTRP )

0.9410 USD UNCHANGED
Last Price Updated: 6:44 PM EST, Dec 1, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Neurotrope Inc

< Previous 1 2 3 4 5 6 Next >
Synthetic Bryostatin Available to Expand Neurodegenerative Indication Trials
Synaptogenix, Inc. (OTC: SNPX) announced today that it has received its first batch of synthetic Bryostatin. The Company has an exclusive licensing agreement with Stanford University ("Stanford") for... 
From PR Newswire
Neurotrope and Metuchen Pharmaceuticals Announce Completion of Merger Forming Petros Pharmaceuticals
- Petros to Grow and Pursue Non-Prescription / Over-The-Counter ("OTC") Strategies for FDA-Approved Erectile Dysfunction Drug Therapy 
From PR Newswire
Neurotrope, Inc. Approves Spin-Off of Neurotrope Bioscience, Inc. and Sets Record and Distribution Dates
Spin-Off Distribution is Conditional Upon the Closing of Neurotrope's Proposed Merger with Metuchen Pharmaceuticals 
From PR Newswire
Neurotrope Announces First Patient Dosed in Long-Term Clinical Trial of Bryostatin in Alzheimer's Disease
- Study Being Conducted in Collaboration with NIH Under a $2.7 Million Grant - 
From PR Newswire
Neurotrope Shareholders to Own 49 Percent of Petros Under Revised Merger Agreement with Metuchen
Neurotrope Shareholders, Currently Representing 34 Percent of Shares Outstanding, Sign Agreement in Support of Merger 
From PR Newswire
Hercules Capital Reports Second Quarter 2020 Financial Results
Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of... 
From Business Wire News Releases
Neurotrope Bioscience Announces Agreement with Worldwide Clinical Trials, to Conduct Ongoing Phase 2 Study of Bryostatin-1, Partially Funded by NIH, for Alzheimer's Disease
Neurotrope, Inc. (Nasdaq: NTRP) ("Neurotrope" or the "Company") today announced that its wholly-owned subsidiary, Neurotrope Bioscience, Inc. ("NBI"), has entered into a services agreement with... 
From PR Newswire
INVESTIGATION ALERT: Halper Sadeh LLP Investigates Whether the Following Mergers are Fair to Shareholders; Investors are Encouraged to Contact the Firm - FNJN, NTRP, GRUB
From ACCESSWIRE
Neurotrope Announces Strategic Partnership with BryoLogyx for Supply of Synthetic Bryostatin-1 and Continuation of the National Cancer Institute (NCI) Trial for Childhood Leukemia
- Neurotrope and Metuchen continue to move toward closing the previously announced merger 
From PR Newswire
BryoLogyx Announces Agreements with Neurotrope to Acquire Bryostatin-1 Immuno-Oncology Data Package, Supply Synthetic Bryostatin-1
BryoLogyx announces agreements with Neurotrope to acquire bryostatin-1 immuno-oncology data package and supply synthetic bryostatin-1 
From Business Wire News Releases
Neurotrope Launches New Long-Term Clinical Trial of Bryostatin with the National Institutes of Health for the Treatment of Patients with Alzheimer's Disease
- New Phase 2 Study to Be Conducted in Collaboration with NIH Under a $2.7 Million Grant - 
From PR Newswire
Neurotrope Announces Investor Update Conference Call
- Management to Host Investor Conference Call on Thursday, May 28, at 11:00 AM ET - 
From PR Newswire
IMPORTANT SHAREHOLDER ALERT: Halper Sadeh LLP Investigates Whether the Following Mergers are Fair to Shareholders; Investors are Encouraged to Contact the Firm - WMGI, MINI, NTRP
From ACCESSWIRE
Neurotrope and Metuchen Pharmaceuticals Announce Merger Agreement to Form Petros Pharmaceuticals, a Men's Health Company
Lead asset Stendra® (avanafil) Looks to Build on $25 Million of 2019 Gross Sales 
From PR Newswire
XpresSpa Appoints Robert Weinstein to Board of Directors
From GlobeNewswire News Releases
World Health Organization Accelerating Diagnostics, Vaccines, Therapeutics For Novel Coronavirus
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
World Health Organization Accelerating Diagnostics, Vaccines, Therapeutics For Novel Coronavirus
Financialnewsmedia.com News Commentary 
From PR Newswire
Neurotrope, Inc. Announces $18 Million Registered Direct Offering
Neurotrope, Inc. (the "Company") (NASDAQ:NTRP) today announced that it has received commitments from institutional investors and pre-existing high net worth individuals to purchase an aggregate of $18... 
From PR Newswire
Neurotrope Provides Corporate Update After Completing Bryostatin-1 Data Analysis for Advanced Alzheimer's Disease Trial
Analysis to adjust for significant baseline imbalance in Severe Impairment Battery scores between treatment groups shows improvement in cognitive function of pre-specified Moderate Stratum patients at... 
From PR Newswire
Neurotrope Announces Review of Strategic Alternatives to Maximize Shareholder Value
Evaluate Potential Opportunities for Lead Therapeutic Candidate Bryostatin 
From PR Newswire
Neurotrope Announces Top-line Results From Confirmatory Phase 2 Study of Bryostatin-1 in Moderate to Severe Alzheimer's Disease
Neurotrope, Inc. (Nasdaq: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today announced that its... 
From PR Newswire
Ellis Martin Report with Neurotrope's (NASDAQ:NTRP) Dr. Daniel Alkon: Reversing Alzheimer's Disease.
From ABN Newswire
Neurotrope Announces Publication Highlighting the Potential of Bryostatin as a Unique Neurorestorative Therapy
-Analysis in Journal, Trends in Pharmacological Sciences, Outlines Bryostatin's Transformative Potential in Combating Alzheimer's Disease- 
From PR Newswire
Neurotrope Announces Corporate Update and Reports Second Quarter 2019 Financial Results
-- Concluded Data Collection in Confirmatory Phase 2 Study of Bryostatin-1 in Moderate to Severe Alzheimer's Disease; Top-line Data Expected During the Third Quarter of 2019 -- 
From PR Newswire
Neurotrope Strategic Advisory Board Members Participating in Key Opinion Leader Call Sponsored by Oppenheimer's Biotechnology Team
Neurotrope Inc. (Nasdaq: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today announced that two of the... 
From PR Newswire
Neurotrope Concludes Data Collection in Confirmatory Phase 2 Clinical Trial of Moderately Severe to Severe Alzheimer's Disease
Top-line efficacy data expected to be announced during the Third Quarter of 2019 
From PR Newswire
Neurotrope to Present at the Alzheimer's Association International Conference; Neurotrope President and Chief Scientific Officer, Dr. Daniel L. Alkon, to Receive Cure Coin Award; Design of Confirmator
Neurotrope, Inc. (Nasdaq: NTRP), a clinical- stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases, including Alzheimer's disease ("AD") is announcing that Dr.... 
From PR Newswire
Neurotrope CEO to Present at the Maxim Group Key Opinion Leader Discussion on Alzheimer's Disease on June 26th, 2019
Neurotrope, Inc. (Nasdaq: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), announced that Dr. Charles S.... 
From PR Newswire
Neurotrope's President and Chief Scientific Officer to Present at the Alzheimer's Solutions Conference at The University of the Sciences in Philadelphia, PA on June 3rd, 2019
Neurotrope, Inc. (Nasdaq: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), announced that Dr. Daniel L.... 
From PR Newswire
Neurotrope to Present at the LD Micro 9th Annual Invitational Conference on June 4, 2019
Neurotrope, Inc. (Nasdaq: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), announced that Dr. Charles... 
From PR Newswire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.